Group items tagged

The Royal Pharmaceutical Society (RPS), the professional leadership body for pharmacists and pharmaceutical scientists in Great Britain, has today announced its proposal to transition into a royal college, becoming the Royal College of Pharmacy. This move follows an 18-month independent review of the RPS constitution and governance and is aimed at strengthening the RPS's leadership role to better support its members. The organisation proposes to enhance its core activities in education, assessment, credentialing, and setting professional standards, ultimately benefiting patients and the public. Under the proposed new structure, the RPS's knowledge business, Pharmaceutical Press, would become a wholly owned subsidiary called Pharmaceutical Press Ltd, accountable to the charitable body of the Royal College of Pharmacy. RPS President Professor Claire Anderson said: "Pharmacy is changing rapidly and the expectations placed upon pharmacists and the wider pharmacy team will have profound repercussions in terms of delivering patient care.

The Royal Pharmaceutical Society (RPS) has responded to the concerns raised by the Guild of Healthcare Pharmacists (GHP) about their proposals to become a Royal College. On behalf of the Guild Council, Rob Connah, president of GHP, recently wrote an open letter to the RPS seeking clarity on the potential impacts of this transition on career progression, time commitments, and other relevant considerations. In response to the Guild Council's inquiries regarding credentialing, RPS chief executive Paul Bennett emphasised that the key purpose of credentialing is to "protect the public and the integrity of the pharmacy profession through assuring patient-focused pharmacists working at advancing levels of post-registration practice." "Defining and assuring post-registration professional standards is a fundamental activity for a royal college and thus fully aligned with our proposals for change," he added. The RPS highlighted the benefits that credentialing can provide both pharmacists and the system.

In September, the Royal Pharmaceutical Society (RPS), the professional leadership body for pharmacists and pharmaceutical scientists in Great Britain, announced its proposal to transition into a Royal College. This significant step, which came following an 18-month independent review of the RPS constitution and governance, aims to strengthen the RPS's leadership role, with the ultimate goal of delivering greater benefits to patients and the public. In an exclusive interview with Pharmacy Business, Tase Oputu, chair of the RPS English Pharmacy Board, discusses the key reasons behind the proposed changes, the potential impact on pharmacists and patients, and her personal journey as the first Black Chair of the RPS Board. Benefits for pharmacists and patients When asked how this transition would benefit pharmacists and patients, Tase says, "I'm excited about RPS' proposals for change. In my view, becoming a Royal College would elevate the status of the profession and strengthen our ability to raise the profile of pharmacy, advocate for change and advance the safe and effective use of medicines for the benefit of patients and the public."

Professor Kamila Hawthorne, chair of the Royal College of GPs, has cautioned that while weight loss drugs hold significant potential to enhance many patients' lives, they are not without risks. She also expressed concern that expanding the roll out of tirzepatide at the scale proposed by the National Institute for Health and Care Excellence (NICE) would have "significant practical and resource implications for the NHS and primary care." The final draft guidance from NICE, published on 5 December, suggests that around 220,000 people living with obesity will be offered the weekly injection, along with a reduced-calorie diet and increased physical activity, over the next three years. Marketed under the brand name Mounjaro by Eli Lilly, tirzepatide is recommended for people with a body mass index (BMI) of more than 35 and at least one weight-related illness. Accepting the request from NHS England to roll out the medication over 12 years, the NICE guidance proposes to prioritise those with the highest clinical need.